ASMB Assembly Biosciences

Assembly Bio Announces Upcoming Investor Events

Assembly Bio Announces Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced two upcoming investor events:

  • 2021 Key Objectives and Anticipated Progress Conference Call and Webcast, concurrent with Q4 and year end 2020 financial results at 5 p.m. ET on Thursday, February 25, 2021

  • SVB Leerink 10th Annual Global Healthcare Conference. John McHutchison AO, MD, Chief Executive Officer and President to participate in fireside chat at 1:40 p.m. ET on Friday, February 26, 2021

Both live audio events will be available in the “” section of Assembly Bio’s website. The archived webcasts will be available on Assembly Bio’s website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV). The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. For more information, visit .

Investor Contact

Assembly Biosciences, Inc.

Lauren Glaser

Senior Vice President, Investor Relations and Corporate Affairs

(415) 521-3828

Media Contact

Sam Brown Inc.

Audra Friis

(917) 519-9577



EN
19/02/2021

Underlying

ASMBAssembly Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Assembly Biosciences

 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Announces Pricing of $175 Million in Equity Finan...

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the “offering”) of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of ...

August 8, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Reports Positive Interim Results from Phase 1b Cl...

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes – 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital lesion rate, also statistically significant, observed with 350 mg weekly oral dose compared to place...

August 8, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study...

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus – Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further pharmacological assessment to be conducted in parallel with Phase 2 preparation – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnol...

August 6, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Reports Second Quarter 2025 Financial Results and...

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates – On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 – – Positive topline data reported for Phase 1b study of ABI-4334, a next-generation highly potent capsid assembly modulator candidate, in participants with chronic hepatitis B virus (HBV) – – Interim data, including a biomarker for target engagement, reported from Phase 1a study in healt...

August 6, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herp...

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop – Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates – – Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted – – Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – SOUTH SAN FRANCISCO, Calif...

July 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch